Control BP prior to treatment initiation & monitor after 1 wk, then every 2 wk for the 1st 2 mth, & mthly thereafter. Monitor patients for clinical symptoms or signs of cardiac dysfunction. Monitor liver function prior to treatment initiation, then every 2 wk for the 1st 2 mth, & mthly thereafter. Risk of renal failure or impairment; initiate prompt management of diarrhea or dehydration/hypovolemia. Monitor for proteinuria prior to treatment initiation & periodically thereafter. Monitor ECG in patients w/ congenital long QT syndrome, CHF, bradyarrhythmias, or those taking drugs known to prolong QT interval including class Ia & III antiarrhythmics. Monitor blood Ca levels at least mthly & replace Ca as necessary. Discontinue permanently following an arterial thrombotic event; or GI perforation of any severity or Grade 3 or 4 fistula. Reversible posterior leukoencephalopathy syndrome (RPLS). Hemorrhagic events. Monitor thyroid function prior to treatment initiation & at least mthly thereafter. Impaired wound healing; withhold treatment for at least 1 wk prior to scheduled surgery; do not administer for at least 2 wk following major surgery & until adequate wound healing. Patients w/ severe renal or hepatic impairment. May impair fertility. Pregnancy. Can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment & for at least 30 days after last dose. Discontinue breastfeeding during treatment & for at least 1 wk after the last dose. Ped patients.